A Long-term Follow-up Cohort Study in Patients With Intraductal Papillary Mucinous Neoplasm

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Oct 21, 2022

Keywords

ClinConnect Summary

This clinical trial is looking to follow patients with a condition called intraductal papillary mucinous neoplasm (IPMN), which is a type of cystic tumor in the pancreas. The main goal of the study is to understand how these patients do over time, what factors might influence their health, and to help create better guidelines for treatment decisions. This research will involve multiple medical centers and will gather information from patients to learn more about the long-term outcomes of living with IPMN.

To participate in this study, individuals must be at least 18 years old and have been diagnosed with IPMN that does not have high-risk features. This means that their condition does not show signs that could indicate a higher chance of developing pancreatic cancer. Participants should be able to understand the study details and give their consent to join. While the study is not yet recruiting volunteers, those who are eligible can expect to share their health information over time, helping researchers gain insights into this condition and improve care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age: 18 years old or above;
• • 2. Diagnosis: Imaging examination showed the presence of intraductal papillary mucinous cystic tumor (IPMN) without high-risk features (including WF and HRS);
• • 3. The patient or family members can understand the study protocol, are willing to participate in the study, and provide written informed consent.
• Exclusion Criteria:
• • 1. The patient's clinical, imaging and auxiliary examination characteristics conform to the surgical indications of the International Association of Pancreatic Diseases (IAP) 2018 guidelines, and the patient has no surgical contraindication;
• • 2. Previous history of pancreatic malignant tumor;
• • 3. There were the following worrisome features (WF) of IPMN found in the past examination: acute pancreatitis, cyst size ≥ 30mm, cyst wall thickening/strengthening, main pancreatic duct diameter of 5-9.9mm, non enhanced mural nodules, sudden change of main pancreatic duct diameter with distal pancreatic atrophy;
• • 4. The following high risk features of IPMN (HRS) were found in the past: obstructive jaundice, enhanced mural nodules or related solid components, and main pancreatic duct\>10mm;
• • 5. The patient or family member could not understand the conditions and objectives of this study.